國立虎尾科技大學 |

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Resistance of Targeted Therapies Excluding Antibodies for Lymphomas/ edited by Andrés J. M. Ferreri.
other author:	Ferreri, Andrés J. M.
Description:	XIII, 138 p. 14 illus., 13 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-3-319-75184-9
ISBN:	9783319751849

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas[electronic resource] /edited by Andrés J. M. Ferreri. - 1st ed. 2018. - XIII, 138 p. 14 illus., 13 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,172196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD – immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .

ISBN: 9783319751849

Standard No.: 10.1007/978-3-319-75184-9doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
LDR:02726nam a22004095i 4500 001 994307
003 DE-He213
005 20200629174001.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319751849 $9 978-3-319-75184-9
024 7 $a 10.1007/978-3-319-75184-9 $2 doi
035 $a 978-3-319-75184-9
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance of Targeted Therapies Excluding Antibodies for Lymphomas $h [electronic resource] / $c edited by Andrés J. M. Ferreri.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XIII, 138 p. 14 illus., 13 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 17
505 0 $a Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD – immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
520 $a In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Ferreri, Andrés J. M. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1285622
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319751832
776 0 8 $i Printed edition: $z 9783319751856
776 0 8 $i Printed edition: $z 9783030091651
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-319-75184-9
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)